in vitro News and Research

RSS

Scientists are developing synthetic COVID-19 antibody to treat sick patients

A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.

24 Apr 2020

Study confirms that neuropeptide somatostatin can improve the brain’s cognitive function

Researchers have confirmed that neuropeptide somatostatin can improve cognitive function in the brain. A research group of Professor Seung-Hee Lee from the Department of Biological Sciences at KAIST found that the application of neuropeptide somatostatin improves visual processing and cognitive behaviors by reducing excitatory inputs to parvalbumin-positive interneurons in the cortex.

24 Apr 2020

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.

23 Apr 2020

Abbott’s fast COVID test poses safety issues, lab workers say

Lab personnel say worries are mounting over the safety of a rapid coronavirus test by Abbott Laboratories that President Donald Trump has repeatedly lauded - particularly, the risk of infection to those handling it.

23 Apr 2020

Anti-SARS-CoV-2 / COVID-19 antibody: In stock and new formats

In mid-March, we announced the availability of an anti-coronavirus antibody shown to recognize SARS-CoV-2 (also referred to as 2019-nCoV or COVID-19). The anti-SARS clone, CR3022, was first described in 2006, and in early 2020, researchers showed the clone has high affinity for the then-termed 2019-nCoV. Scientists worldwide are now exploring this antibody as a candidate for mono- as well as combination-therapy development.

From Absolute Antibody Ltd 23 Apr 2020

Study: Somatostatin treatment in cerebral cortex may improve visual processing, cognitive behaviors

23 Apr 2020

Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis

Accelerating antibody discovery using picodroplet technology for single cell analysis to condense discovery times down to 1-2 days.

From Fluidic Sciences and Sphere Bio 22 Apr 2020

Is hydroxychloroquine effective against COVID-19?

Following the emergence of a novel coronavirus in Wuhan, China, in the last month of 2019, it has spread globally to produce the first pandemic of the 21st century. The virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected over 2.5 million and killed more than 177,000 people as of April 22, 2020.

22 Apr 2020

Study shows how tumor cells respond to lack of nutrients

Some solid tumors have a very high growth rate, which often leads to a lack of vascularization due to the impossibility to develop, at the same time, the blood vessels that accompany and nourish it.

21 Apr 2020

Bio-Rad Introduces Anti-Ipilimumab Antibodies

Bio-Rad Laboratories, Inc has extended its range of recombinant monoclonal anti-idiotypic antibodies.

21 Apr 2020

Mutations in novel coronavirus make it more dangerous

A new report published on the preprint server medRxiv in April 2020 reveals that the novel coronavirus SARS-CoV-2 shows the presence of new mutations acquired within infected human cases, which significantly increase its ability to cause human disease.

20 Apr 2020

HIV-1 and influenza antivirals not effective for treating mild-to-moderate COVID-19 cases

An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol--antivirals that are used in some countries against HIV-1 and to treat influenza , respectively--as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.

20 Apr 2020

Research suggests Nelfinavir and Cepharanthine as potential anti-SARS-CoV-2 agents

A new study published in the journal bioRxiv in April 2020 reports the identification of a promising multidrug treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for causing COVID-19 disease. The team predicts that this combination will prevent the virus from reproducing, hence both halting the transmission and progress of the disease.

19 Apr 2020

Hydroxychloroquine and azithromycin treatment in 80 COVID-19 patients: short-term outcomes

The COVID-19 pandemic is still spreading around the world and affecting nearly 2.4 million people, with over 164,000 dead so far. With neither vaccine nor proven therapeutic drug being available so far, the need of the hour is for effective treatment. Now, a new study reports the potential usefulness of a combination of hydroxychloroquine and azithromycin as a treatment in mild cases of COVID-19 infection and urges the need for further evaluation and widespread use if its findings are confirmed.

19 Apr 2020

Alternative imaging technique shows promise for safer heart procedures

In the first study of its kind, Johns Hopkins researchers provide evidence that an alternative imaging technique could someday replace current methods that require potentially harmful radiation.

17 Apr 2020

New cyclic peptide enhances blood-brain barrier penetration

A Japanese research team has developed a cyclic peptide (a chain of amino acids bonded circularly) that enhances blood-brain barrier penetration.

17 Apr 2020

An alternative imaging technique for safer heart procedures

Researchers provide evidence that an alternative imaging technique could replace methods requiring harmful radiation.

17 Apr 2020

Novel FIMP protein may help orchestrate mammalian fertilization

Fertilization is a fundamental process in sexual reproduction when the combination of male and female gametes blends genetic material to create a new unique individual. Now, researchers from Japan have identified a new factor that may help orchestrate this vitally complex life event.

16 Apr 2020

ACE2 genetic variants may influence coronavirus disease progression

Researchers in British Columbia have identified a set of gene variants that are likely to influence disease progression from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to COVID-19 disease.

15 Apr 2020